Therefore, while [18F]AV‐1451 might retain a role in tracking disease by visualising the distribution and/or severity of neuropathology in a person with frontotemporal dementia, it is unlikely to have utility for cohort selection for disease modifying trials that target tau or TDP‐43‐specific disease mechanisms. This evidence concerns the gene TARDBP and frontotemporal dementia.